AR059686A1 - Piperazinas terapeuticas - Google Patents
Piperazinas terapeuticasInfo
- Publication number
- AR059686A1 AR059686A1 ARP070100831A ARP070100831A AR059686A1 AR 059686 A1 AR059686 A1 AR 059686A1 AR P070100831 A ARP070100831 A AR P070100831A AR P070100831 A ARP070100831 A AR P070100831A AR 059686 A1 AR059686 A1 AR 059686A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- aryl
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de piperazina, composiciones que comprenden tales compuestos, y métodos de preparacion del compuesto. Los compuestos son inhibidores e la funcion PDE4 y son utiles para mejorar la funcion cognitiva, retardo mental, trastornos psicoticos y neuroticos y tumor cerebral. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula 1: en donde: R1 es H, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, alcanoiloxi C1-6, cicloalquilo C3-8, cicloalquil C3-8- alquilo C1-6, halo(C1-6)alquilo, arilo, aril(C1-6)alquilo, aril(C1-6)alcoxi, aril(C1-6)alcanoilo, het, het(C1-6)alquilo, het(C1-6)alcoxi, o het(C1-6)alcanoilo; n es 1 o 2; m es 1 o 2; W es O, S, o dos hidrogenos; X es O o N-Y-R4, Y es un enlace directo, -CH2-, -C(=O)-, -C(=S)-, -O-, -C(=O)O-, - OC(=O)-, -C(=O)Nra-, -S-, -S(=O), -S(=O)2, o -S(=O)2Nra-; R4 es H, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, hidroxi, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, halo(C1-6)alquilo, hidroxi(C1- 6)alquilo, alcoxicarbonilo C1-6, carboxi, arilo, aril(C1-6)alquilo, het, NRdRe, C(=O)NRdRe, NRdRe(C1-6)alquilo, o het(C1-6)alquilo; Ra es H, alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6-alquilo C2-6, o cicloalquil C3-8-alquilo C1-6; Z es un anillo fenilo sustituido con uno o más sustituyentes seleccionados en forma independiente entre alquilo C1-6, halo(C1-6)alquilo, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, alcoxi C1-6, halo(C1-6)alcoxi, cicloalquiloxi C3-8, y cicloalquil C3-8-alcoxi C1-6; o Z es un anillo fenilo que está fusionado con un sistema de anillo mono o bicíclico saturado, parcialmente insaturado o aromático que comprende entre aproximadamente 3 y aproximadamente 8 átomos seleccionados entre carbono, oxígeno, y NRb, en donde el sistema de anillo mono o bicíclico de Z está opcionalmente sustituido con uno o más Rc, y en donde el anillo fenilo que está fusionado con el sistema de anillo mono o bicíclico está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre alquiloC1-6, halo (C1-6)alquilo, cicloalquilo C3-8, cicloalquil 3-8-alquilo C1-6, alcoxi C1-6, halo(C2-6)alcoxi, cicloalquiloxi C3-8, cicloalquil C3-8-alcoxi C1-6; Rb está ausente , H, alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6-alquilo C2-6, o cicloalquil C3-8-alquilo C1-6; Rc es alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, alcanoiloxi C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, halo(C1-6)alquilo, arilo, aril(C1-6)alquilo, aril(C1-6)alcoxi, aril(C1-6)alcanoilo, het, het(C1-6)alquilo, het(C1-6)alcoxi, o het(C1-6)alcanoilo; cada Rd y Re es en forma independiente H, hidroxi, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6,alqueniloxi C2-6, alquiniloxi C2-6, alcanoilo C1-6, alcoxicarbonilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, arilo, aril (C1-6)alquilo, NRfRg, o aril(C1-6)alcoxi; y cada Rf y Rg es en forma independiente H, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, arilo, aril(C1-6)alquilo, o aril(C1-6)alcoxi; o Rf y Rg junto con el nitrogeno al cual están unidos forman un anillo pirrolidino, piperidino, piperazino, morfolino, o tiomorfolino; en donde cualquier grupo arilo o het de R1 o R4 está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre alquilo C1-6, fenilo, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, alcanoiloxi C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, halo(C1-6)alquilo, cicloalquiloxi C3-8, cicloalquil C3-8-alcoxi C1-6, halo(C2-6)alcoxi, ciano, nitro, halo, carboxi o NRdRe; y en donde el anillo con un contenido de X está opcionalmente sustituido sobre carbon con uno o más halo, alquilo C1-6, o alcoxi C1-6, o una sal aceptable para uso farmacéutico del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77729106P | 2006-02-28 | 2006-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059686A1 true AR059686A1 (es) | 2008-04-23 |
Family
ID=38279005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070100831A AR059686A1 (es) | 2006-02-28 | 2007-02-28 | Piperazinas terapeuticas |
Country Status (15)
Country | Link |
---|---|
US (4) | US7829713B2 (es) |
EP (2) | EP1989188B1 (es) |
JP (1) | JP2009528363A (es) |
CN (1) | CN101490017B (es) |
AR (1) | AR059686A1 (es) |
AU (1) | AU2007221021B2 (es) |
BR (1) | BRPI0708337A2 (es) |
CA (1) | CA2644069A1 (es) |
ES (1) | ES2462240T3 (es) |
HK (1) | HK1185063A1 (es) |
IL (1) | IL193674A0 (es) |
NZ (1) | NZ570844A (es) |
SG (2) | SG171634A1 (es) |
TW (1) | TW200804309A (es) |
WO (1) | WO2007100852A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200804309A (en) * | 2006-02-28 | 2008-01-16 | Helicon Therapeutics Inc | Therapeutic piperazines |
US8927546B2 (en) * | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
AR065709A1 (es) * | 2007-03-12 | 2009-06-24 | Biolipox Ab | Piperidinonas y composiciones farmaceuticas que las contienen usadas para el tratamiento de la inflamacion. procesos de obtencion. |
GB0722769D0 (en) * | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
DK2142529T3 (da) | 2007-04-27 | 2014-02-10 | Purdue Pharma Lp | Trpv1-antagonister og anvendelser deraf |
AR077969A1 (es) * | 2009-08-31 | 2011-10-05 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina comomoduladores de s1p |
EP2539706B1 (en) * | 2010-02-24 | 2015-03-04 | Research Triangle Institute | Arylpiperazine opioid receptor antagonists |
WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
RS55701B1 (sr) | 2011-06-22 | 2017-07-31 | Purdue Pharma Lp | Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe |
KR102148355B1 (ko) | 2012-07-27 | 2020-08-26 | 사토 파머슈티컬 가부시키가이샤 | 디플루오로메틸렌 화합물 |
CA2894130A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
US9611257B2 (en) | 2012-12-21 | 2017-04-04 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
WO2014100695A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
HUE040323T2 (hu) | 2012-12-21 | 2019-02-28 | Epizyme Inc | PRMT5-inhibitorok és alkalmazásaik |
JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
EP2970212B1 (en) | 2013-03-14 | 2018-04-25 | Dart Neuroscience (Cayman) Ltd. | Substituted pyridine and pyrazine compounds as pde4 inhibitors |
WO2016022605A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
BR112022008113A2 (pt) | 2019-10-31 | 2022-07-19 | Escape Bio Inc | Formas sólidas de um modulador de receptor s1p |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2996507A (en) * | 1959-09-09 | 1961-08-15 | Abbott Lab | Piperazine compounds |
US3306903A (en) * | 1965-10-07 | 1967-02-28 | Council Scient Ind Res | 1-aminopyridyl-4-(phenyl or pyridyl)-piperazines and intermediates |
FR2262964B1 (es) * | 1973-04-05 | 1978-07-28 | Synthelabo | |
DE2345422C2 (de) * | 1973-09-08 | 1983-12-22 | Dr. Karl Thomae Gmbh, 7950 Biberach | Substituierte Isochinolyl-arylpiperazine diese enthaltende Arzneimittel sowie Verfahren zu deren Herstellung |
AT330777B (de) * | 1973-09-08 | 1976-07-26 | Thomae Gmbh Dr K | Verfahren zur herstellung von neuen isochinolinderivaten und deren salzen |
GB1575904A (en) * | 1976-04-23 | 1980-10-01 | Lilly Industries Ltd | Phenyl piperazines |
US4093726A (en) * | 1976-12-02 | 1978-06-06 | Abbott Laboratories | N-(2-benzimidazolyl)-piperazines |
US4666911A (en) * | 1981-07-14 | 1987-05-19 | Taiho Pharmaceutical Company Limited | Allophanoylpiperazine compound and analgesic composition containing same as active ingredient |
FR2533212A1 (fr) * | 1982-09-22 | 1984-03-23 | Lipha | Benzo-et thieno-triazine-1,2,3 ones-4 procedes de preparation et medicaments les contenant |
FR2551753B2 (fr) * | 1982-09-22 | 1986-02-28 | Lipha | Benzotriazine-1,2,3-ones-4, procede de preparation et medicaments les contenant |
DE3442860A1 (de) * | 1984-11-24 | 1986-05-28 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 5-alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3- on-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
ATE81975T1 (de) * | 1984-12-21 | 1992-11-15 | Duphar Int Res | Arzneimittel mit psychotroper wirkung. |
US4845100A (en) * | 1985-04-12 | 1989-07-04 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same |
IT1187751B (it) * | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
US4960776A (en) | 1987-01-28 | 1990-10-02 | A. H. Robins Company, Inc. | 4-aryl-N-(alkylaminoalkyl, heterocyclicamino and heterocyclicamino)alkyl)-1-piperazinecarboxamides |
US5204482A (en) * | 1988-07-28 | 1993-04-20 | Hoffman-Laroche Inc. | Compounds for treating and preventing cognitive diseases and depression and methods of making same |
US5086055A (en) * | 1990-12-24 | 1992-02-04 | A. H. Robins Company, Incorporated | Series of 5-[-(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives useful in the treatment of allergic conditions |
TW197429B (es) * | 1991-05-01 | 1993-01-01 | Dtsuka Seiyaku Kk | |
FR2680172B1 (fr) * | 1991-08-05 | 1993-11-19 | Fabre Medicament Pierre | Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique. |
DE4241563A1 (de) * | 1992-12-10 | 1994-06-16 | Basf Ag | Neue Triazolochinazoline, ihre Herstellung und Verwendung |
JPH10152470A (ja) * | 1996-09-25 | 1998-06-09 | Yoshitomi Pharmaceut Ind Ltd | ピペラジン化合物 |
DE19744026A1 (de) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
AU754734B2 (en) | 1997-11-04 | 2002-11-21 | Pfizer Products Inc. | Indazole bioisostere replacement of catechol in therapeutically active compounds |
PE20010628A1 (es) | 1999-10-01 | 2001-06-18 | Takeda Chemical Industries Ltd | Compuestos de amina ciclica, su produccion y su uso |
EP2258689A1 (en) | 2000-03-16 | 2010-12-08 | Biolipox AB | Benzylated PDE4 inhibitors |
US8153646B2 (en) | 2000-08-10 | 2012-04-10 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
KR20040012851A (ko) * | 2001-05-22 | 2004-02-11 | 뉴로젠 코포레이션 | 멜라닌 농축성 호르몬 수용체 리간드: 치환된1-벤질-4-아릴 피페라진 유사체 |
AU2002326948A1 (en) | 2001-09-18 | 2003-04-01 | Bristol-Myers Squibb Company | Piperizinones as modulators of chemokine receptor activity |
US7589199B2 (en) | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
WO2004013130A1 (en) | 2002-08-02 | 2004-02-12 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
DE60330150D1 (en) | 2002-08-08 | 2009-12-31 | Memory Pharmaceutical Corp | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren |
PT1539753E (pt) * | 2002-09-16 | 2009-12-10 | Glaxo Group Ltd | Compostos de pirazolo(3,4-b)piridina e sua utilização como inibidores da fosfodiesterase |
SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
DE10315571A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Pyrazolverbindungen |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0322510D0 (en) | 2003-09-25 | 2003-10-29 | Glaxo Group Ltd | Novel compounds |
US20050250789A1 (en) * | 2004-04-20 | 2005-11-10 | Burns David M | Hydroxamic acid derivatives as metalloprotease inhibitors |
US7585859B2 (en) * | 2004-05-06 | 2009-09-08 | Plexxikon, Inc. | PDE4B inhibitors and uses therefor |
US7429666B2 (en) | 2004-06-10 | 2008-09-30 | Merck Frosst Canada Ltd. | Pyridine analogs as C5a antagonists |
EP1807391A4 (en) | 2004-10-29 | 2010-01-06 | Astrazeneca Ab | NOVEL SULFONAMIDE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND FOR THE TREATMENT OF INFLAMMATORY DISEASES |
GT200600042A (es) | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
KR20080028964A (ko) | 2005-06-27 | 2008-04-02 | 엑셀리시스, 인코포레이티드 | 피라졸계 lxr 변조제 |
CA2621275A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
US8927546B2 (en) * | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
TW200804309A (en) * | 2006-02-28 | 2008-01-16 | Helicon Therapeutics Inc | Therapeutic piperazines |
EP2060575A1 (de) * | 2006-04-19 | 2009-05-20 | Boehringer Ingelheim International GmbH | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
CA2722582A1 (en) | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf. | Biaryl pde4 inhibitors for treating inflammation |
-
2007
- 2007-02-27 TW TW096106660A patent/TW200804309A/zh unknown
- 2007-02-27 EP EP07751890.0A patent/EP1989188B1/en not_active Not-in-force
- 2007-02-27 SG SG201103039-2A patent/SG171634A1/en unknown
- 2007-02-27 CN CN2007800143821A patent/CN101490017B/zh not_active Expired - Fee Related
- 2007-02-27 EP EP12160350.0A patent/EP2562168B1/en not_active Not-in-force
- 2007-02-27 CA CA002644069A patent/CA2644069A1/en not_active Abandoned
- 2007-02-27 JP JP2008557345A patent/JP2009528363A/ja active Pending
- 2007-02-27 SG SG201103040-0A patent/SG171635A1/en unknown
- 2007-02-27 ES ES12160350.0T patent/ES2462240T3/es active Active
- 2007-02-27 US US11/679,782 patent/US7829713B2/en not_active Expired - Fee Related
- 2007-02-27 WO PCT/US2007/005159 patent/WO2007100852A1/en active Application Filing
- 2007-02-27 BR BRPI0708337-8A patent/BRPI0708337A2/pt not_active IP Right Cessation
- 2007-02-27 NZ NZ570844A patent/NZ570844A/en not_active IP Right Cessation
- 2007-02-27 AU AU2007221021A patent/AU2007221021B2/en not_active Ceased
- 2007-02-28 AR ARP070100831A patent/AR059686A1/es unknown
-
2008
- 2008-08-25 IL IL193674A patent/IL193674A0/en unknown
-
2010
- 2010-08-23 US US12/861,213 patent/US8338405B2/en active Active
- 2010-09-01 US US12/873,452 patent/US8501745B2/en not_active Expired - Fee Related
-
2013
- 2013-07-31 US US13/955,037 patent/US20140038945A1/en not_active Abandoned
- 2013-08-27 HK HK13110046.8A patent/HK1185063A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1989188A1 (en) | 2008-11-12 |
IL193674A0 (en) | 2009-05-04 |
US8338405B2 (en) | 2012-12-25 |
EP2562168B1 (en) | 2014-04-16 |
EP1989188B1 (en) | 2015-07-22 |
SG171635A1 (en) | 2011-06-29 |
US8501745B2 (en) | 2013-08-06 |
US7829713B2 (en) | 2010-11-09 |
US20110065688A1 (en) | 2011-03-17 |
SG171634A1 (en) | 2011-06-29 |
AU2007221021A1 (en) | 2007-09-07 |
HK1185063A1 (en) | 2014-02-07 |
US20140038945A1 (en) | 2014-02-06 |
EP2562168A1 (en) | 2013-02-27 |
CN101490017A (zh) | 2009-07-22 |
BRPI0708337A2 (pt) | 2011-05-24 |
ES2462240T3 (es) | 2014-05-22 |
AU2007221021B2 (en) | 2013-01-17 |
US20070203124A1 (en) | 2007-08-30 |
JP2009528363A (ja) | 2009-08-06 |
WO2007100852A1 (en) | 2007-09-07 |
CA2644069A1 (en) | 2007-09-07 |
US20110065689A1 (en) | 2011-03-17 |
NZ570844A (en) | 2011-11-25 |
CN101490017B (zh) | 2013-01-23 |
TW200804309A (en) | 2008-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059686A1 (es) | Piperazinas terapeuticas | |
AR061564A1 (es) | Derivados de isoindoles, composiciones farmaceuticas y usos | |
ES2666870T3 (es) | Derivado de dispiropirrolidina | |
AR073920A1 (es) | Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion. | |
PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
AR066502A1 (es) | Compuestos amino- heterociclicos | |
AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
AR088970A1 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina | |
GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
CO2018008799A2 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de jak | |
CL2007001555A1 (es) | Compuestos derivados de 4-amino-pirido[3,2-e]pirazinas; inhibidores de fosfodiesterasa 10 (pde10); procedimeinto de preparacion; composicion framaceutica; combinacion farmaceutica, y sus uso en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y otros trastornos psicoticos. | |
AR057984A1 (es) | DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE | |
AR071300A1 (es) | Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento | |
AR041734A1 (es) | Compuestos de alquino con efecto antagonico de la hcm y medicamentos que contienen estos compuestos | |
AR034264A1 (es) | Derivados azepino(4,5-b)indol sustituidos y composiciones farmaceuticas | |
PA8615701A1 (es) | Derivados de dihidrobenzofuranilo alcanamina y metodos para su uso. | |
AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
AR077796A1 (es) | Moduladores de receptores de glutamato metabotropicos | |
AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
RU2019143759A (ru) | Новое соединение бифенила или его соль | |
ECSP066459A (es) | Miméticos de glucocorticoides, métodos de preparación, composiciones farmacéuticas y usos de los mismos | |
AR051395A1 (es) | Derivados de imidazo- benzodiazepina, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos, y usos en terapeutica | |
AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
AR076688A1 (es) | Derivados de isoquinolin-1(2h)-ona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |